中国临床药理学杂志2016，Vol.32Issue(12)：1088-1090,3.DOI:10.13699/j.cnki.1001-6821.2016.12.010
卡培他滨联合奥沙利铂治疗晚期食管胃交界部腺癌的临床研究
Clinical trial of capecitabine combined with oxaliplatin in the treatment of advanced oesphago-gastric junction adenocarcinoma
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of capecitabine combined with oxaliplatin in the treatment of advanced esophago-gastric junction adenocarcinoma.Methods Eighty patients with advanced esophago -gastric junction adenocarcinoma were random-ly divided into control group ( n=40 ) and treatment group ( n=40 ).Control group was treated with 75 mg· m-2 docetaxel, intravenous infu-sion, day 1 +20 mg· m-2 cisplatin , intravenous infusion, day 1 +750 mg· m-2 5-fluorouracil, continuous infusion for 120 h, from day 1.Treatment group was received 120 mg · m-2 oxaliplatin , intravenous infusion , qd ( after 2 weeks treatment , discontinuation 1 week ) +7.5 mg · kg -1 recombinant human endostatin , intravenous infusion , qd +2000 mg· m-2 capecitabine, oral, bid(after 2 weeks treatment, discon-tinuation 1 week).Two groups were received 3 courses of treatment , 21 d for a course.The clinical efficacy , levels of tumor specific macromole-cular glycoprotein antigen 19 -9 ( CA199 ) , cancer embryo antigen (CEA), vascular endothelial growth factor (VEGF) and cell transmembrane notch ligand 4 (DLL4), and the inci-dence of adverse drug reactions were compared between two groups.Results After treatment, the total effective rate in treatment group was significantly higher than that in control group ( 90.00% vs 72.50%, P<0.05 ).The levels of CA199, CEA, VEGF, DLL4 after treatment in two groups were significantly lower than those before treatment ( P<0.05 ) , and after treatment , these indexes in treatment group were lower than those in control group with signifi-cant difference ( P<0.05 ).The incidence of adverse drug reactions in treatment was lower than that in control group with significant difference ( 15.00% vs 32.50%, P<0.05 ).Conclusion Capecitabine combined with oxaliplatin have a definitive clinical efficacy and safety for the treatment of advanced esophago -gastric junction adenocarcinoma , which can significantly reduce the levels of CA 199, CEA, VEGF and DLL4.关键词
卡培他滨/奥沙利铂/食管胃交接部腺癌/安全性Key words
capecitabine/oxaliplatin/esophageal gastric junction adenocarcinoma/safety分类
医药卫生引用本文复制引用
任志丽,张瑞新,吴晓旭..卡培他滨联合奥沙利铂治疗晚期食管胃交界部腺癌的临床研究[J].中国临床药理学杂志,2016,32(12):1088-1090,3.基金项目
唐山市科学技术研究与发展计划指导项目基金资助项目 （）
